<DOC>
	<DOCNO>NCT02418689</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety novel pan-HER inhibitor , NOV120101 ( Poziotinib ) , HER2-overexpressed recurrent stage IV breast cancer patient receive least 2 prior HER2-directed regimen .</brief_summary>
	<brief_title>Poziotinib Patients With HER2+ Recurrent Stage IV BC Who Have Received Least 2 Prior HER2-directed Regimens</brief_title>
	<detailed_description>To evaluate efficacy NOV120101 ( Poziotinib ) therapeutic agent HER2-overexpressed recurrent stage IV breast cancer , patient receive least two prior HER2-directed regimen enrol study . Subjects receive NOV120101 ( Poziotinib ) 12 mg PO daily 2 week follow 1-week drug-free interval cycle disease progression unacceptable toxicity development . Progression Free Survival ( PFS ) analyze primary endpoint trial . Secondary endpoint include PFS rate 12 week , ORR , DCR , OS TTP also analyze .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1. Who give agreement collection tumor tissue specimen suitable biomarker research 2 . ECOG performance status â‰¤ 2 3. Who receive follow treatment Taxanebased chemotherapy least two HER2targeted* therapy include Trastuzumab . * lapatinib , TDM1 ( trastuzumab emtansine ) , pertuzumab 4 . Adequate hematological , hepatic renal function 1. Who receive NOV120101 prior participation study 2 . Patients expect exhibit hypersensitivity IP components 3 . Any concurrent chemotherapy 4 . Concurrent prior radiotherapy within 4 week study participation . However , patient additional lesion major lesion complete recover treatmentrelated toxicity radiotherapy limited area palliative therapy allow participate study 5 . History symptomatic unstable angina congestive heart failure ; arrhythmia require medication ; clinically significant myocardial infarction cardiac disease within 6 month study participation relatedsignificant risk expect 6 . Patients whose left ventricle ejection fraction ( LVEF ) institutional low limit normal . However , low limit normal define site , low limit normal 50 % . 7 . Concurrent active hepatic biliary disease ( exception Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease ) 8 . History concurrent ongoing/active infection , uncontrolled disease include , limited , psychiatric illness/social situation may limit compliance study procedures 9 . Prior chemo , immuno , surgical therapy within 3 week , hormone therapy within 1 week IP administration 10 . History primary malignancy breast cancer . 11 . Patients central nervous system ( CNS ) metastases . 12 . Patients receive expect receive bisphosphonate prophylactic use without bonerelated disease trial , exception treatment bone metastases osteoporosis initiate prior IP administration . 13 . Clinically significant recent acute gastrointestinal disorder diarrhea major symptom 14. Who unstable unresolved severe adverse event ( ) 15 . Pregnancy breastfeed 16 . Women childbearing potential men unwilling use adequate contraception abstinent trial least 2 month end treatment</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>